Related Experiment Video

Updated: Jul 11, 2025

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.5K

Acute heart failure: mechanisms and pre-clinical models-a Scientific Statement of the ESC Working Group on Myocardial

Michele Ciccarelli1, Inês Falcão Pires2, Johann Bauersachs3

  • 1Cardiovascular Research Unit, Department of Medicine and Surgery, University of Salerno, Via Salvador Allende, 84081 Baronissi, Italy.

Cardiovascular Research
|November 15, 2023
PubMed

Insights

Acute heart failure (AHF) management lags behind chronic heart failure (CHF) due to limited understanding of its molecular basis. This statement explores AHF trajectories and potential molecular targets for improved treatment.

Area of Science:

  • Cardiology
  • Molecular Medicine
  • Translational Research

Background:

  • Chronic heart failure (CHF) treatments have advanced, but acute heart failure (AHF) therapies remain stagnant.
  • Limited pre-clinical models and understanding of molecular mechanisms hinder AHF progress.
  • Diverse AHF phenotypes complicate therapeutic strategies.

Purpose of the Study:

  • To outline the various pathways from acute to chronic heart failure.
  • To identify key molecular mechanisms driving AHF progression.
  • To explore novel molecular targets for AHF treatment.

Main Methods:

  • Review of current literature on AHF pathophysiology.
  • Analysis of factors influencing AHF trajectories (etiology, genetics, environment, comorbidities).
  • Discussion of potential molecular targets for therapeutic intervention.

Main Results:

  • AHF progression to CHF is multifactorial, influenced by a complex interplay of factors.
  • Specific molecular pathways are implicated in different AHF phenotypes.
  • Identification of potential targets offers new avenues for AHF management.

Conclusions:

  • A deeper understanding of AHF molecular mechanisms is crucial for therapeutic advancement.
  • Targeting specific molecular pathways could improve acute outcomes and prevent progression to CHF.
  • Further research into pre-clinical models and molecular targets is warranted.

Keywords:
Acute heart failureNew strategiesPhenotypesPre-clinical modelsScientific statementTherapeutic managementTrajectories

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.9K
A Modified Technique for Transverse Aortic Constriction in Mice04:52

A Modified Technique for Transverse Aortic Constriction in Mice

Published on: August 18, 2022

4.6K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
14
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
17